FDA Panel Backs Novo Diabetes Drugs, With Conditions
Overcoming fears of cardiovascular risks, Novo Nordisk A/S won backing Thursday for new insulin treatments Tresiba and Ryzodeg from a U.S. Food and Drug Administration advisory panel, potentially setting the stage...To view the full article, register now.
Already a subscriber? Click here to view full article